Patent ID: 6596876
Filing Date: 2003-07-22
Classification: C07D

Abstract:
A compound selected from the group of compounds represented by Formula I: wherein:R2 and R4 are each independently: (1) hydrogen, (2) alkyloxy, or (3) halogen; R3 is independently in each occurrence: (1) NR8R9 (2) â€”(CH2)mCONR8R9, wherein m is an integer from 0 to 3, (3) â€”(CH2)mSO2NR8R9, wherein m is an integer from 0 to 3, (4) â€”(CH2)mNR7COR9, wherein m is an integer from 0 to 3, (5) â€”(CH2)mNR7SO2R9, wherein m is an integer from 0 to 3, (6) â€”(CH2)mNR7C(V)NR8R9, wherein V is S or 0, and m is an integer from 0 to 3, or (7) â€”O(CH2)nZ wherein n is an integer from 1 to 4 and Z is: cycloalkyl, hydroxyalkyl, cycloalkyloxy, heterocyclyl, aryloxy, heteroaryl, â€”COR9, â€”CONR8R9, â€”SO2R9, â€”SO2NR8R9, â€”NR7SO2R9, or unsubstituted aryl or mono-, di-, or tn-substituted awl, the substituents being independently selected from alkyl, halogen, or alkyloxy; R7 and R8 are each independently in each occurrence: (1) hydrogen, (2) alkyl, or (3) hydroxyalkyl; R9 is independently in each occurrence: (1) alkyl, (2) cycloalkyl, (3) arylalkyl, (4) hydroxyalkyl, (5) haloalkyl, (6) heterocyclyl, (7) unsubstituted aryl or mono-, di-, ortni-substituted aryl, the substituents being independently selected from alkyl, halogen, or alkyloxy, or (8) heteroaryl; or R8 and R9 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered moniocyclic saturated or unsaturated ring, and in which the ring is optionally substituted or unsubstituted with oxo; or R7 and R9 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered monocyclic saturated or unsaturated ring, and in which the ring is optionally substituted or unsubstituted with oxo; or a pharmaceutically acceptable salt or a crystal form thereof.